There were no differences in baseline C-peptide, baseline insulin, or bsAUC for C-peptide between GLP-2 and placebo study days during hypoglycemia, euglycemia, or hyperglycemia (Fig. 2G-2L, Table 3). This evidence concerns the gene INS and Hyperglycemia.